215 related articles for article (PubMed ID: 8356244)
1. The role of chemotherapy in the treatment of prostatic carcinoma.
Tonato M; Bracarda S
Rays; 1993; 18(1):87-93. PubMed ID: 8356244
[No Abstract] [Full Text] [Related]
2. How effective is cytotoxic chemotherapy for disseminated prostatic carcinoma?
Eisenberger MA; Kennedy P; Abrams J
Oncology (Williston Park); 1987 Jun; 1(4):59-71. PubMed ID: 3079482
[TBL] [Abstract][Full Text] [Related]
3. [Prognostic and therapeutic aspects of prostatic carcinoma].
Studer UE
Schweiz Rundsch Med Prax; 1988 May; 77(20):545-50. PubMed ID: 3291053
[No Abstract] [Full Text] [Related]
4. [The late results of the combined hormonal chemoradiation treatment of prostatic cancer].
Sviridova TV; Mardynskiĭ IuS; Tsodikova LB; Rozhkov OV
Urol Nefrol (Mosk); 1996; (1):31-4. PubMed ID: 8659040
[TBL] [Abstract][Full Text] [Related]
5. Chemotherapy: is it effective in treatment of prostatic cancer?
Murphy GP
Urology; 1984 Nov; 24(5 Suppl):41-7. PubMed ID: 6388094
[TBL] [Abstract][Full Text] [Related]
6. [Antineoplastic chemotherapies (including hormone therapy). Classification and mechanism of action].
Clavel M
Rev Prat; 1991 Dec; 41(26):2759-65. PubMed ID: 1808694
[No Abstract] [Full Text] [Related]
7. A critical assessment of the role of chemotherapy for endocrine-resistant prostatic carcinoma.
Eisenberger MA; Bezerdjian L; Kalash S
Urol Clin North Am; 1987 Nov; 14(4):695-706. PubMed ID: 3314063
[TBL] [Abstract][Full Text] [Related]
8. Small cell carcinoma of the prostate with excellent treatment results.
Koukourakis G; Kouloulias V; Psyri A; Zacharias G; Maravelis G; Kostakopoulos A
J BUON; 2008; 13(3):442-3. PubMed ID: 18979565
[No Abstract] [Full Text] [Related]
9. Is chemotherapy ready for clinical use in prostatic cancer patients?
Jones WG
Prog Clin Biol Res; 1988; 269():159-76. PubMed ID: 3293058
[No Abstract] [Full Text] [Related]
10. Immunotherapy for prostate cancer - recent progress in clinical trials.
Kipp RT; McNeel DG
Clin Adv Hematol Oncol; 2007 Jun; 5(6):465-74, 477-9. PubMed ID: 17679921
[TBL] [Abstract][Full Text] [Related]
11. Hormonal chemotherapy.
Dunzendorfer U
Prog Clin Biol Res; 1989; 303():197-203. PubMed ID: 2780648
[No Abstract] [Full Text] [Related]
12. Second line treatment of hormone refractory prostatic cancer patients.
Collste LG
Prog Clin Biol Res; 1990; 357():29-37. PubMed ID: 2217473
[No Abstract] [Full Text] [Related]
13. [Hormonal, radiation and combined therapy of locally advanced prostatic cancer (T3NXM0)].
Pavlov AS; Loran OB; Simakina EP; Tomkevich BA; Repina AG; Gribova RG
Urologiia; 2005; (4):24-6. PubMed ID: 16158741
[TBL] [Abstract][Full Text] [Related]
14. [Role of mitoxantrone in the treatment of hormone-independent metastatic cancer of the prostate].
Culine S
Prog Urol; 2002 Feb; 12(1 Suppl 2):31-5. PubMed ID: 11980025
[No Abstract] [Full Text] [Related]
15. The management of end-stage carcinoma of the prostate: philosophy and fact.
Robinson MR
Prog Clin Biol Res; 1990; 357():39-44. PubMed ID: 2217476
[No Abstract] [Full Text] [Related]
16. Androgen depletion/repletion in combination with chemotherapy: strategy for secondary treatment of metastatic prostatic cancer.
Santen RJ; English H; Rohner T; Drago J; Lipton A; Harvey H; Simmonds M; Boucher A; Glode LM; Wettlaufer J
Prog Clin Biol Res; 1985; 185A():359-71. PubMed ID: 4034580
[No Abstract] [Full Text] [Related]
17. [Treatment of advanced pancreatic cancer].
Lersch C; Classen M
Dtsch Med Wochenschr; 1990 Mar; 115(9):340-2. PubMed ID: 1689634
[No Abstract] [Full Text] [Related]
18. Malignant melanoma.
Schwartsmann G; Parkinson DR
Cancer Chemother Biol Response Modif; 1993; 14():577-93. PubMed ID: 8312120
[No Abstract] [Full Text] [Related]
19. Chemotherapy for endocrine resistant cancer of the prostate.
Eisenberger MA
Prog Clin Biol Res; 1990; 359():155-64; discussion 177-80. PubMed ID: 2284289
[No Abstract] [Full Text] [Related]
20. [Oncology update '89. I].
Pfreundschuh M
Med Klin (Munich); 1989 Nov; 84(11):542-7. PubMed ID: 2687674
[No Abstract] [Full Text] [Related]
[Next] [New Search]
